NCT02451982View on ClinicalTrials.gov

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

76

Participants

Timeline

Start Date

March 28, 2016

Primary Completion Date

October 31, 2025

Study Completion Date

May 31, 2026

Conditions

Pancreatic Cancer

Interventions

DRUG

Cyclophosphamide

200 mg/m2 IV

BIOLOGICAL

GVAX pancreatic cancer

5x10\^8 cells intradermal injection

DRUG

Nivolumab

480 mg IV

DRUG

Urelumab

8 mg IV

DRUG

BMS-986253

2400 mg IV

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER